If the rise in HIV counts is due to release of HIV in reservoirs and near 100% receptor occupancy still exists then there would be no effect. It would actually help in emptying reservoirs sooner. If it's a rapid rise in CCR5 that leronlimab fails to bind then it could be a problem in a complete cure. What we don't know (but Cytodyn would) is if those blips do not occur after very long term use of leronlimab or not.

What they're looking at in AAV vector leronlimab is a functional cure which means below 200 copies per millimeter all the time. With the body itself producing leronlimab it would almost certainly mean greater than an equivalent 700mg dose so it should cover the rise in CCR5.